Schlagwort: Phase 2a-Studie
“We still believe we’re an undiscovered gem.”
What drives an experienced biotech leader to join a company like TOPAS, and why does he believe that they’re an undiscovered gem in the...
CatalYm unterstreicht Wirksamkeit von Visugromab
Das Münchener Biotech-Unternehmen CatalYm hat gestern aktuelle Phase-2a-Ergebnisse seiner laufenden GDFATHER-2-Studie (GDF-15 Antibody-mediaTed Human Effector Cell Relocation Phase 2) (NCT04725474) in einer mündlichen Präsentation...